ENVB

SEC source: 0001967056-26-000003 · ownership.xml · nonDerivative · entry 1

Coveney Kevin Michael · CIK 0001967056 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,746

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

SEC source: 0001597334-26-000002 · ownership.xml · nonDerivative · entry 1

PASQUALONE FRANK · CIK 0001597334 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,423

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0001883914-26-000003 · ownership.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 271,479

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

SEC source: 0001239463-26-000002 · ownership.xml · nonDerivative · entry 1

WEBB MICHAEL D · CIK 0001239463 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,416

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0001761753-26-000003 · ownership.xml · nonDerivative · entry 1

Kegler George A. · CIK 0001761753 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,418

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0001645282-26-000002 · ownership.xml · nonDerivative · entry 1

Schabacker Marcus · CIK 0001645282 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,418

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0002025032-26-000002 · ownership.xml · nonDerivative · entry 1

DeWitt Sheila · CIK 0002025032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,306

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0001883966-26-000003 · ownership.xml · nonDerivative · entry 1

Facchini Peter J. · CIK 0001883966 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,755

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

F2 · balance_after: On October 28, 2025, the common stock of the Company began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001193125-25-337184 · ownership.xml · nonDerivative · entry 1

DeWitt Sheila · CIK 0002025032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,788

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

F2 · balance_after: On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "January Reverse Stock Split"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the"October Reverse Stock Split" together with the January Reverse Stock Split, the "Reverse Stock Splits"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.

SEC source: 0001193125-25-337182 · ownership.xml · nonDerivative · entry 1

Kegler George A. · CIK 0001761753 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,900

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

F2 · balance_after: On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "January Reverse Stock Split"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the"October Reverse Stock Split" together with the January Reverse Stock Split, the "Reverse Stock Splits"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.

SEC source: 0001193125-25-337179 · ownership.xml · nonDerivative · entry 1

PASQUALONE FRANK · CIK 0001597334 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,904

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

F2 · balance_after: On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "January Reverse Stock Split"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the"October Reverse Stock Split" together with the January Reverse Stock Split, the "Reverse Stock Splits"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.

SEC source: 0001193125-25-337178 · ownership.xml · nonDerivative · entry 1

Schabacker Marcus · CIK 0001645282 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,900

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

F2 · balance_after: On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "January Reverse Stock Split"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the"October Reverse Stock Split" together with the January Reverse Stock Split, the "Reverse Stock Splits"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.

SEC source: 0001193125-25-337175 · ownership.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,355

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

F2 · balance_after: On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001193125-25-337172 · ownership.xml · nonDerivative · entry 1

WEBB MICHAEL D · CIK 0001239463 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,898

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

F2 · balance_after: On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "January Reverse Stock Split"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the"October Reverse Stock Split" together with the January Reverse Stock Split, the "Reverse Stock Splits"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.

SEC source: 0001193125-25-337171 · ownership.xml · nonDerivative · entry 1

Coveney Kevin Michael · CIK 0001967056 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,413

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

F2 · balance_after: On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001415889-25-012679 · form4-05122025_050505.xml · nonDerivative · entry 1

Coveney Kevin Michael · CIK 0001967056 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,584

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

F2 · balance_after: On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001415889-25-012678 · form4-05122025_050503.xml · nonDerivative · entry 1

Facchini Peter J. · CIK 0001883966 · CHIEF INNOVATION OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,058

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

F2 · balance_after: On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001415889-25-012677 · form4-05122025_050501.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,711

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

F2 · balance_after: On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001415889-24-025063 · form4-10112024_111005.xml · nonDerivative · entry 1

DeWitt Sheila · CIK 0002025032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,845

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in full on December 31, 2024, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0001415889-24-025061 · form4-10112024_111015.xml · nonDerivative · entry 1

Kegler George A. · CIK 0001761753 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,053

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in full on December 31, 2024, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0001415889-24-025059 · form4-10112024_111054.xml · nonDerivative · entry 1

Schabacker Marcus · CIK 0001645282 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,053

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in full on December 31, 2024, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0001415889-24-025057 · form4-10112024_111026.xml · nonDerivative · entry 1

WEBB MICHAEL D · CIK 0001239463 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,733

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in full on December 31, 2024, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0001415889-24-025055 · form4-10112024_111008.xml · nonDerivative · entry 1

PASQUALONE FRANK · CIK 0001597334 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,733

F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in full on December 31, 2024, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

SEC source: 0001415889-24-025052 · form4-10112024_111058.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,829

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

SEC source: 0001415889-24-025050 · form4-10112024_111008.xml · nonDerivative · entry 1

Facchini Peter J. · CIK 0001883966 · CHIEF INNOVATION OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,856

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

SEC source: 0001415889-24-025048 · form4-10112024_111038.xml · nonDerivative · entry 1

Coveney Kevin Michael · CIK 0001967056 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,500

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

SEC source: 0001415889-24-005259 · form4-02262024_090238.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,196

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

SEC source: 0001415889-24-005253 · form4-02262024_090248.xml · nonDerivative · entry 1

Facchini Peter J. · CIK 0001883966 · CHIEF INNOVATION OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,856

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

SEC source: 0001415889-24-005251 · form4-02262024_090246.xml · nonDerivative · entry 1

Coveney Kevin Michael · CIK 0001967056 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,500

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

SEC source: 0001415889-23-013430 · form4-09192023_090952.xml · nonDerivative · entry 1

PASQUALONE FRANK · CIK 0001597334 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000

SEC source: 0001493152-23-007662 · ownership.xml · nonDerivative · entry 1

Coveney Kevin Michael · CIK 0001967056 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,500

F1 · balance_after: Represents restricted stock units (the "RSUs") granted to the reporting person. For each vested RSU, the reporting person will be entitled to receive one share of common stock.

F2 · balance_after: The RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on March 13, 2024.

SEC source: 0001493152-23-002802 · ownership.xml · nonDerivative · entry 1

Facchini Peter J. · CIK 0001883966 · Chief Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,865

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal installments, with the first installment vesting upon the one year anniversary of the date of issuance.

SEC source: 0001493152-23-002801 · ownership.xml · nonDerivative · entry 1

Hagel Jillian Marie · CIK 0001883891 · Vice President of Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,802

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal annual installments, with the first installment vesting upon the one year anniversary of the date of issuance.

SEC source: 0001493152-23-002800 · ownership.xml · nonDerivative · entry 1

Kanubaddi Avani · CIK 0001838498 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,346

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal annual installments, with the first installment vesting upon the one year anniversary of the date of issuance.

F2 · balance_after: Includes 38,346 restricted stock units previously reported on Table II.

SEC source: 0001493152-23-002799 · ownership.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,196

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal annual installments, with the first installment vesting upon the one year anniversary of the date of issuance.

SEC source: 0001493152-22-002203 · ownership.xml · derivative · entry 1

Ward Carter Julian · CIK 0001467874 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 744,429

Underlying: Common Stock · 744,429 shares

Expires not disclosed

F1 · security: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock.

F2 · derivative.exercise_price: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively.

F2 · derivative.exercise_date: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively.

F2 · derivative.expiration_date: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively.

SEC source: 0001493152-22-002201 · ownership.xml · derivative · entry 1

Kanubaddi Avani · CIK 0001838498 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,127,787

Underlying: Common Stock · 1,127,787 shares

Expires not disclosed

F1 · security: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock.

F2 · derivative.exercise_price: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively.

F2 · derivative.exercise_date: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively.

F2 · derivative.expiration_date: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively.

SEC source: 0001493152-23-002449 · ownership.xml · nonDerivative · entry 2

Hagel Jillian Marie · CIK 0001883891 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,802

F3 · shares: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $119.00, $130.50 and $143.50, respectively.

F2 · balance_after: Includes 10,633 shares previously held through the Hagel 2020 Family Trust, which were distributed to the reporting person and are now owned directly.

SEC source: 0001493152-23-002449 · ownership.xml · nonDerivative · entry 1

Hagel Jillian Marie · CIK 0001883891 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,302

F1 · shares: The reporting person received the RSUs as a one-time signing bonus upon the commencement of the reporting person's employment with the Company. 50% of the RSUs shall vest over 2 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest over 2 years in equal annual installments, if the Company's average VWAP exceeds 110% and 120% of $158.925, respectively.

F2 · balance_after: Includes 10,633 shares previously held through the Hagel 2020 Family Trust, which were distributed to the reporting person and are now owned directly.

SEC source: 0001493152-23-002452 · ownership.xml · nonDerivative · entry 2

Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,856

F3 · shares: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $119.00, $130.50 and $143.50, respectively.

F2 · balance_after: Includes 10,633 shares previously held through the Facchini 2020 Family Trust, which were distributed to the reporting person and are now owned directly.

SEC source: 0001493152-23-002452 · ownership.xml · nonDerivative · entry 1

Facchini Peter J. · CIK 0001883966 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,356

F1 · shares: The reporting person received the restricted stock units (RSUs) as a one-time signing bonus upon the commencement of the reporting person's employment with the Company. 50% of the RSUs shall vest over 2 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest over 2 years in equal annual installments, if the Company's average VWAP exceeds 110% and 120% of $158.925, respectively.

F2 · balance_after: Includes 10,633 shares previously held through the Facchini 2020 Family Trust, which were distributed to the reporting person and are now owned directly.

SEC source: 0001493152-23-002453 · ownership.xml · nonDerivative · entry 2

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,196

F3 · shares: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $119.00, $130.50 and 143.50, respectively.

F2 · balance_after: Includes 13,822 shares previously held through the Tucker 2020 Family Trust, which were distributed to the reporting person and are now owned directly.

SEC source: 0001493152-23-002453 · ownership.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,196

F1 · shares: The reporting person received the RSUs as a one-time signing bonus upon the commencement of the reporting person's employment with the Company. 50% of the RSUs shall vest over 2 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest over 2 years in equal annual installments, if the Company's average VWAP exceeds 110% and 120% of $158.925, respectively.

F2 · balance_after: Includes 13,822 shares previously held through the Tucker 2020 Family Trust, which were distributed to the reporting person and are now owned directly.

SEC source: 0001493152-21-023865 · ownership.xml · derivative · entry 4

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,290

Underlying: Common Stock · 13,290 shares

Expires 2023-09-16

F6 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F8 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 50,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

F3 · ownership.nature: Held indirectly through the Tucker 2020 Family Trust, a trust controlled by Dr. Tucker.

SEC source: 0001493152-21-023865 · ownership.xml · derivative · entry 3

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 664,503

Underlying: Common Stock · 664,503 shares

Expires 2025-05-26

F6 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F7 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,500,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

F3 · ownership.nature: Held indirectly through the Tucker 2020 Family Trust, a trust controlled by Dr. Tucker.

SEC source: 0001493152-21-023865 · ownership.xml · derivative · entry 2

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,351

Underlying: Common Stock · 199,351 shares

Expires 2026-04-05

F4 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option.

F5 · price: Received in exchange for options to acquire 750,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation.

SEC source: 0001493152-21-023865 · ownership.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 691,083

F1 · price: Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.

F2 · price: Received in exchange for 2,600,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement.

F3 · ownership.nature: Held indirectly through the Tucker 2020 Family Trust, a trust controlled by Dr. Tucker.

SEC source: 0001493152-21-023862 · ownership.xml · derivative · entry 1

Thompson Bradley George · CIK 0001883869 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,160

Underlying: Common Stock · 53,160 shares

Expires 2026-04-05

F1 · price: Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.

F2 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option.

F3 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F4 · price: Received in exchange for options to acquire 200,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation.

SEC source: 0001493152-21-025237 · ownership.xml · derivative · entry 4

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footenote

Disclosed balance after: 13,290

Underlying: Common Stock · 13,290 shares

Expires 2023-09-16

F4 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F7 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 50,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

F3 · ownership.nature: Held indirectly through the Tucker 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Tucker and his family.

SEC source: 0001493152-21-025237 · ownership.xml · derivative · entry 3

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footenote

Disclosed balance after: 531,602

Underlying: Common Stock · 531,602 shares

Expires 2025-05-26

F4 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F6 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,000,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

F3 · ownership.nature: Held indirectly through the Tucker 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Tucker and his family.